Non-Covalent BTK Inhibitor Approved for CLL

(MedPage Today) -- The FDA expanded the label of pirtobrutinib (Jaypirca) to include the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) following two prior lines of therapy, the agency announced on Friday. An...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news